1K
1K9.F Caredx Inc
- Market cap
- EUR 3.91B
- P/E
- 35.8x
- P/B
- 9.59x
- ROE
- 37.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1K9.F undervalued?
Graham numberThe Graham number of Caredx Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Caredx Inc fundamental analysis
No fundamental analysis for Caredx Inc yet.
Caredx Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Caredx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant pa…
Full company profileCaredx Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Caredx Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 40.6M | 48.3M | 76.6M | 127M | 192M | 296M | 322M | 280M | 334M | 380M | 519M |
| Gross Profit | 19.5M | 27.0M | 43.6M | 81.6M | 129M | 199M | 210M | 178M | 224M | 257M | 374M |
| Operating Income | -24.8M | -17.2M | -14.6M | -24.5M | -22.5M | -29.7M | -77.2M | -107M | -55.5M | -25.1M | 13.6M |
| EBITDA | - | -13.4M | -10.3M | -19.0M | -13.0M | -17.8M | -61.2M | -87.2M | -35.8M | -4.66M | 38.1M |
| Net Income | -39.5M | -55.5M | -46.8M | -22.0M | -18.7M | -30.7M | -76.6M | -190M | 52.5M | -21.4M | 177M |
| EPS | - | -1.92 | -1.13 | -0.52 | -0.38 | -0.58 | -1.43 | -3.52 | 0.98 | -0.42 | 3.37 |
| Balance Sheet | |||||||||||
| Total Assets | 76.7M | 83.6M | 131M | 152M | 369M | 567M | 543M | 467M | 491M | 413M | 641M |
| Total Liabilities | 57.0M | 89.5M | 34.8M | 52.7M | 90.8M | 101M | 112M | 205M | 113M | 110M | 174M |
| Shareholders' Equity | 19.5M | -6.13M | 95.9M | 99.0M | 278M | 466M | 431M | 261M | 378M | 303M | 467M |
| Cash & Short-term Investments | 17.3M | 16.9M | 64.6M | 38.2M | 135M | 348M | 89.9M | 82.2M | 115M | 65.4M | 250M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.5M | -14.3M | -4.01M | -2.77M | 33.4M | -19.3M | -25.2M | -18.4M | 38.0M | 42.0M | 63.5M |
| Capital Expenditure | 549K | 186K | 2.04M | 2.20M | 7.11M | 13.6M | 21.2M | 9.24M | 6.48M | 6.59M | 9.72M |
| Free Cash Flow | - | -14.5M | -11.2M | -6.12M | 23.1M | -39.6M | -49.6M | -27.6M | 31.6M | 35.4M | 53.8M |
| Ratios | |||||||||||
| ROE | -202.6% | - | -48.7% | -22.2% | -6.7% | -6.6% | -17.8% | -72.8% | 13.9% | -7.0% | 37.9% |
| ROA | -51.4% | -66.4% | -35.8% | -14.5% | -5.1% | -5.4% | -14.1% | -40.8% | 10.7% | -5.2% | 27.6% |
| Net Profit Margin | -97.1% | -114.8% | -61.1% | -17.3% | -9.7% | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% | 34.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Caredx Inc dividends
Caredx Inc has not paid dividends in the last 9 fiscal years.
Who owns Caredx Inc
- Insiders 2.98%
- Institutions 97.02%
- Public & others 0.00%
- Shares outstanding 52.5M
- Free float 50.8M
Caredx Inc company profile
- Company name
- Caredx Inc
- Ticker
- 1K9.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 761
- Fiscal year end
- December
- Address
- 8000 Marina Boulevard, Brisbane, CA, United States, 94005
- Phone
- 415 287 2300
- Website
- caredx.com
About Caredx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Caredx Inc management
10- Mr. John Walter Hanna Jr.President, CEO & Director · born 1980
- Mr. Keith S. Kennedy C.F.A., CPACFO & COO · born 1970
- Mr. Jeffrey A. NovackGeneral Counsel & Secretary · born 1984
- Ms. Jessica MengChief Commercial Officer · born 1975
- Mr. Kashif RathoreChief Technology Officer
- Dr. Robert N. Woodward Ph.D.Chief Scientific Officer
- Ms. Nina D. DekaHead of Investor Relations
- Ms. Natasha Moshirian WagnerVice President of Corporate Communications
- Ms. Marica Grskovic Ph.D.Chief Strategy Officer
- Ms. Jing Huang Ph.D.Chief Data & Artificial Intelligence Officer